Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

X
Trial Profile

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Olomorasib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenoid cystic carcinoma; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Intestinal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms KRAS G12C
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 04 Jun 2024 Results(As of 30 October 2023, n=157 pts) focusing Pan-tumor activity of olomorasib , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2024 Results ( as of 30 October 2023, n=50 pts) assessing efficacy and safety of olomorasib in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2024 According to an Eli Lilly and Company Media Release, data from this study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top